The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021.

A recent study reveals a surge in the use of GLP-1 medications, such as Ozempic and Wegovy, among younger age groups. Originally developed for diabetes, these drugs are now popular for weight loss ...

Changes in eating habits are impacting some categories, like snacks, more than others. Taking GLP-1 drugs reduces a person's appetite significantly, slowing down the emptying of the stomach and making ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, ...

The use of behavioral health services decreased dramatically for patients prescribed GLP-1 drugs during the study period.

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.

In study of patients with diabetes and obesity, class of drugs also tied to lower mortality risk ...

Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well.